This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
by Zacks Equity Research
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth outlook.
BMYPositive Net Change ANIPNegative Net Change ADMANegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Ahan Chakraborty
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of stability vs. upside.
NVOPositive Net Change LLYPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
by Zacks Equity Research
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
GSKPositive Net Change ANIPNegative Net Change LQDANegative Net Change
biotechs
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
by Sundeep Ganoria
ImmunityBio bets on Anktiva label expansion to drive growth, but intense Big Pharma competition and premium valuation raise questions about its next phase.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change IBRXNegative Net Change
biotechs medical pharmaceuticals
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
by Zacks Equity Research
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the latest study.
PFENegative Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
by Zacks Equity Research
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
NVSNegative Net Change ANIPNegative Net Change ADMANegative Net Change LQDANegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the Recent Label Expansion of BMY's Sotyktu Boost Its Prospects?
by Ekta Bagri
BMY's Sotyktu PsA approval boosts its immunology push, expands market reach, and sharpens its competitive stance amid pressure from legacy drug declines.
NVSNegative Net Change BMYPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Theravance's Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
GSKPositive Net Change TBPHNo Net Change VTRSNegative Net Change
biotechs
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why
by Zacks Equity Research
PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.
JNJPositive Net Change ABBVPositive Net Change PTGXPositive Net Change
biotechs
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
by Zacks Equity Research
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
RHHBYPositive Net Change SRPTNegative Net Change ARWRNegative Net Change
biotechs gene-editing gene-therapy medical pharmaceuticals